Clinical trials: Age Related Maculopathy
Age Related Maculopathy
The Role of Macular Pigment in Patients With Age-related Macular Degeneration
In the industrialised world age-related macular degeneration (ARMD) is the leading cause for legal blindness beyond the age of 50 years.
- Trial name
- NCT00494325
- Where
- Switzerland
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Age-Related Macular Degenerations., Subfoveal Neovascularization.
Treatment of Conditions With Open Label-Anecortave Acetate Sterile Suspension ( 15mg.) Where Lesions do Not Meet Acceptable Criteria for Standard Care.
A compassionate method of treatment is offered to patients where lesions do not meet acceptable criteria for standard therapy. Visudyne (Photodynamic Therapy) and laser photocoagulation treatment (a treatment using heat from a…
- Trial name
- NCT00211484
- Testing
- Anecortave Acetate
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Manhattan Eye, Ear & Throat Hospital
Macular Degeneration
Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Japanese Patients With Neovascular AMD
This study will evaluate the safety and to characterize the systemic pharmacokinetics of free and vascular endothelial growth factor (VEGF)-bound abicipar following multiple monthly intravitreal injections of abicipar in Japanese…
- Trial name
- PINE (NCT03335852)
- Testing
- Abicipar pegol
- Where
- 5 sites in Japan
- Volunteers
- 11 people
- Sponsor
- Allergan
Macular Degeneration
Analysis of naïve Patients With Age-related Macular Degeneration Neovascular Type and Treated With Ranibizumab (Lucentis®) in Treat-and-extend at the CHU Brugmann.
Age-related macular degeneration (AMD) is a leading cause of blindness in people over 50 years old. Neovascular AMD, the most severe form and the most severe is characterized by the appearance, spread and growth of subretinal…
- Trial name
- NCT04988178
- Testing
- Data extraction from medical files
- Where
- Belgium
- Volunteers
- 34 people
- Sponsor
- Brugmann University Hospital
Age-Related Macular Degeneration
Seven-year Outcomes Following Intensive Anti-VEGF Therapy in Wet AMD
The aim of this study was to assess long-term benefits of intensive aflibercept and ranibizumab anti-VEGF therapy in patients with exudative AMD.
- Trial name
- NCT05678517
- Testing
- Anti-VEGF
- Where
- 2 sites in Hungary
- Volunteers
- 47 people
- Sponsor
- Semmelweis University
Neovascular (Wet) Age-Related Macular Degeneration
Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
The primary objectives of the study are to determine the safety of high-dose aflibercept (hereafter referred to as HD) and to determine if HD provides greater intraocular pharmacodynamic (PD) effect and/or longer duration of…
- Trial name
- CANDELA (NCT04126317)
- Testing
- aflibercept, High-dose aflibercept
- Where
- 46 sites in United States, Puerto Rico
- Volunteers
- 106 people
- Sponsor
- Regeneron Pharmaceuticals
Age Related Macular Degeneration
Molecular Imaging Exploration of Ocular Angiogenic Activity and Evaluation of Its Interest in the Therapeutic Follow-up of Patients With AMD (Age-related Macular Degeneration)
The main objective of this pilot study is to evaluate the ability of 68Ga-NODAGA-RGD PET imaging to demonstrate, in patients with unilateral AMD, a molecular therapeutic response to intraocular antiangiogenic injections at the…
- Trial name
- DMLA-RGD (NCT04005443)
- Testing
- radiopharmaceutical
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Neovascular (Wet) Age-Related Macular Degeneration
Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration
This Phase 1b/2a study will primarily investigate the safety and tolerability of EYC-0305 delivered by intravitreal (IVT) injection every 24 weeks in patients with neovascular (wet) age-related macular degeneration (AMD).
- Trial name
- OVERTURE (NCT07587515)
- Testing
- EYC-0305
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Eyconis INC.
Age Related Macular Degeneration, Polypoidal Choroidal Vasculopathy
An Open Label-study to Compare the Efficacy of Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy
Polypoidal choroidal neovasculopathy (PCV) is a subtype of wet age related macula degeneration (AMD) occuring more commonly in the Asian population.
- Trial name
- NCT03117634
- Testing
- Treat and Extend with Aflibercept 2mg, Fixed Dosing with Aflibercept 2mg
- Where
- Singapore
- Volunteers
- 54 people
- Sponsor
- Singapore National Eye Centre
Aged Macular Degeneration
Omega-3-fatty Acids on Age-related Macular
Aim: To demonstrate the short-term multi focal electroretinogram (mfERG) effect of oral omega-3-fatty acids in the triglyceride form on dry age-related macular degeneration (AMD).
- Trial name
- Omega 3 (NCT01258335)
- Testing
- Omega 3, Olive Oil
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Mid Atlantic Retina
Macular Degeneration, Age-Related Macular Degeneration
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person.
- Conditions
- Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
- Trial name
- MALBEC (NCT07440225)
- Testing
- Tiespectus, Aflibercept
- Where
- 132 sites in United States, Argentina and 10 more
- Volunteers
- 960 people
- Sponsor
- EyeBiotech Ltd.
Macular Degeneration
A Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration
Age-Related Macular Degeneration (AMD) is a degenerative eye disease of the retina that causes a progressive loss of central vision. AMD is the leading cause of legal blindness among adults age 50 or older in the Western world.
- Trial name
- NCT00333476
- Testing
- MSI-1256F (Squalamine Lactate)
- Where
- 9 sites in United States
- Volunteers
- 140 people
- Sponsor
- Genaera Corporation
Geographic Atrophy Secondary to Age-related Macular Degeneration
Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe
This is a phase 3, open-label study to evaluate the safety of pegcetacoplan in a prefilled syringe (PFS)
- Trial name
- NCT07214740
- Testing
- APL-2, Pegcetacoplan
- Where
- 5 sites in United States
- Volunteers
- 44 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Age Related Macular Degeneration
Bevacizumab Versus Ranibizumab in Age Related Macular Degeneration
To report the short term anatomic and visual acuity response after intravitreal injection of bevacizumab and ranibizumab in patients with choroidal neovascularization secondary to age-related macular degeneration.
- Trial name
- AxL-2009 (NCT01014468)
- Testing
- Ranibizumab (Intravitreal injection), Bevacizumab (Intravitreal injection)
- Where
- Brazil
- Volunteers
- 500 people
- Sponsor
- Instituto de Olhos de Goiania
Neovascular Age-Related Macular Degeneration
Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)
The goal of this study is to evaluate the overall safety and efficacy of LX102 gene therapy for nAMD.
- Trial name
- NCT06196840
- Testing
- LX102 subretinal injection, Aflibercept intravitreal injection
- Where
- 11 sites in China
- Volunteers
- 50 people
- Sponsor
- Innostellar Biotherapeutics Co.,Ltd
Stargardt Disease, Diabetic Retinopathy
Oxidative Stress In Stargardt Disease, Age Related Macular Degeneration and Diabetic Retinopathy
In this study, markers of oxidative stress will be measured in the aqueous humour of stargardt disease, age related macular degeneration and diabetic retinopathy patients compared to controls.
- Conditions
- Stargardt Disease, Diabetic Retinopathy, Macular Degeneration (Age Related)
- Trial name
- NCT02875704
- Testing
- Anterior Chamber (AC) Tap
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Johns Hopkins University
Age-Related Macular Degeneration
IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD
This is a prospective, single-blind, randomized study to evaluate intravitreal aflibercept injection (IAI) versus sham as prophylaxis against conversion to neovascular age-related macular degeneration (AMD) in "high-risk"…
- Trial name
- PRO-CON (NCT02462889)
- Testing
- Intravitreal aflibercept injection
- Where
- 4 sites in United States
- Volunteers
- 128 people
- Sponsor
- Jeffrey S Heier
Macular Degeneration
Combination Therapy for Neovascular Age Related Macular Degeneration
Exudative age related macular degeneration (ARMD) is most common cause of blindness in old population. It is clear that no single therapy addresses the multifactorial pathogenesis of the disease.
- Trial name
- NCT00447031
- Testing
- intravitreal bevacizumab and triamcinolone acetonide
- Where
- South Korea
- Sponsor
- Yonsei University
Central Retinal Vein Occlusion, Choroidal Neovascularization
A Research Study to Evaluate the Effects of Repeated Intravitreal Injections on Bacteria Around the Eye
This is a research study to evaluate the effects of repeated intravitreal injections on bacteria around the eye.
- Conditions
- Central Retinal Vein Occlusion, Choroidal Neovascularization, Age-related Macular Degeneration, Branch Retinal Vein Occlusion
- Trial name
- NCT01531842
- Testing
- Conj flora Antibiotic resistance
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mid Atlantic Retina
Age-Related Macular Degeneration
Dark Adaptation in Participants With Age-Related Macular Degeneration
Background: Macular degeneration can cause permanent loss of central vision. This vision is important for seeing details. Age-related macular degeneration (AMD) is the leading cause of vision loss in people over 55 in the United…
- Trial name
- NCT03225131
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- National Eye Institute (NEI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.